Join us for a 1-hour webinar

Laboratory Developed Test (LDT) validation is one of the most challenging aspects of the implementation of a Next Generation Flow (NGF) assay. In this webinar, David M Foureau will discuss how he navigated the process of validating a high sensitive Multiple Myeloma MRD flow assay following CAP/CLIA standards and how he successfully bridged the gap between the flow laboratory and the clinic.

Key learning points:

• Short overview of MRD testing in Multiple Myeloma
• Research insights on MRD NGF specimen collection and adequacy
• Research insights on MRD NGF assay performance
• Building a clinical validation plan for flow cytometry-based assay
• MRD NGF clinical validation highlights (specificity, sensitivity, robustness)
• General considerations on running MRD NGF clinical test

Currently working as the Research Group Director at the Levine Cancer Institute (Atrium Health), in 2013 David M Foureau created the Immune Monitoring Core Laboratory at Atrium Health (formerly Carolinas Healthcare System) which is specialized in immunoassay development, validation and implementation for immune-oncology applications.

7 PM GMT+2 (Madrid, Spain)
7 PM GMT+2 (Amsterdam, Netherlands)
1 AM GMT+8 (Beijing, China)
3 AM GMT +1 (Sydney, Australia)
2 PM GMT-3 (Rio de Janeiro, Brasil)
1 PM GMT-4 (New York, NY, USA)
10 AM GMT-7 (Los Angeles, CA, USA)
5 PM GMT (London, United Kingdom)